{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:08:59Z","timestamp":1794456539958,"version":"4.9.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1038\/s41591-023-02518-x","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T16:05:27Z","timestamp":1692893127000},"page":"3077-3089","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8318-5455","authenticated-orcid":false,"given":"Joris L.","family":"Vos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Burman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8625-8218","authenticated-orcid":false,"given":"Swati","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conall W. R.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara A.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James V.","family":"Fetten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren S.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Kriplani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth K.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vatche","family":"Tchekmedyian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Katabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-2896","authenticated-orcid":false,"given":"Fengshen","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine Y.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaineb","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4104-5876","authenticated-orcid":false,"given":"Vladimir","family":"Makarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghvendra M.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Ostrovnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-012X","authenticated-orcid":false,"given":"Charlotte L.","family":"Zuur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9873-5862","authenticated-orcid":false,"given":"Nadeem","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2109-3221","authenticated-orcid":false,"given":"David G.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9645-3896","authenticated-orcid":false,"given":"Christopher A.","family":"Klebanoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9265-0283","authenticated-orcid":false,"given":"Timothy A.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-3742","authenticated-orcid":false,"given":"Alan L.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4417-2280","authenticated-orcid":false,"given":"Luc G. T.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"2518_CR1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1034\/j.1601-0825.2002.02870.x","volume":"8","author":"PM Speight","year":"2002","unstructured":"Speight, P. M. & Barrett, A. W. Salivary gland tumours. Oral. Dis. 8, 229\u2013240 (2002).","journal-title":"Oral. Dis."},{"key":"2518_CR2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1053\/j.semdp.2003.09.001","volume":"20","author":"AK Bennett","year":"2003","unstructured":"Bennett, A. K., Mills, S. E. & Wick, M. R. Salivary-type neoplasms of the breast and lung. Semin. Diagn. Pathol. 20, 279\u2013304 (2003).","journal-title":"Semin. Diagn. Pathol."},{"key":"2518_CR3","unstructured":"WHO Classification of Head and Neck Tumours 4th edn (eds EI-Naggar, A. K., Chan, J. K., Grandis, J. R., Takata, T. & Slootweg, P.) (IARC, 2017)."},{"key":"2518_CR4","doi-asserted-by":"crossref","unstructured":"Laurie, S. A., Ho, A. L., Fury, M. G., Sherman, E. & Pfister, D. G. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 12, 815\u2013824 (2010).","DOI":"10.1016\/S1470-2045(10)70245-X"},{"key":"2518_CR5","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1200\/JCO.2005.05.3025","volume":"24","author":"SA Laurie","year":"2006","unstructured":"Laurie, S. A. & Licitra, L. Systemic therapy in the palliative management of advanced salivary gland cancers. J. Clin. Oncol. 24, 2673\u20132678 (2006).","journal-title":"J. Clin. Oncol."},{"key":"2518_CR6","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"2518_CR7","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","volume":"41","author":"RB Cohen","year":"2018","unstructured":"Cohen, R. B. et al. Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study. Am. J. Clin. Oncol. 41, 1083\u20131088 (2018).","journal-title":"Am. J. Clin. Oncol."},{"key":"2518_CR8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijrobp.2020.08.018","volume":"109","author":"U Mahmood","year":"2021","unstructured":"Mahmood, U. et al. A randomized phase 2 study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 109, 134\u2013144 (2021).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2518_CR9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2022.05.007","volume":"171","author":"C Even","year":"2022","unstructured":"Even, C. et al. Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. Eur. J. Cancer 171, 259\u2013268 (2022).","journal-title":"Eur. J. Cancer"},{"key":"2518_CR10","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1200\/JCO.2019.37.15_suppl.6083","volume":"37","author":"J Fayette","year":"2019","unstructured":"Fayette, J. et al. NISCAHN: a phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent\/metastatic (R\/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group. J. Clin. Oncol. 37, 6083\u20136083 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2518_CR11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jso.24266","volume":"114","author":"T Mukaigawa","year":"2016","unstructured":"Mukaigawa, T. et al. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. J. Surg. Oncol. 114, 36\u201343 (2016).","journal-title":"J. Surg. Oncol."},{"key":"2518_CR12","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277\u20131290 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2518_CR13","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.18.01042","volume":"37","author":"N Ready","year":"2019","unstructured":"Ready, N. et al. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J. Clin. Oncol. 37, 992\u20131000 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2518_CR14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2518_CR15","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1002\/cncr.32792","volume":"126","author":"X Mimica","year":"2020","unstructured":"Mimica, X. et al. Distant metastasis of salivary gland cancer: incidence, management, and outcomes. Cancer 126, 2153\u20132162 (2020).","journal-title":"Cancer"},{"key":"2518_CR16","doi-asserted-by":"crossref","first-page":"18740","DOI":"10.1073\/pnas.0909114106","volume":"106","author":"M Persson","year":"2009","unstructured":"Persson, M. et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc. Natl Acad. Sci. USA 106, 18740\u201318744 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2518_CR17","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-16-0637","volume":"22","author":"MG Dalin","year":"2016","unstructured":"Dalin, M. G. et al. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. Clin. Cancer Res. 22, 4623\u20134633 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2518_CR18","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01178-z","volume":"8","author":"MG Dalin","year":"2017","unstructured":"Dalin, M. G. et al. Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. Nat. Commun. 8, 1197 (2017).","journal-title":"Nat. Commun."},{"key":"2518_CR19","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1172\/JCI128227","volume":"129","author":"AS Ho","year":"2019","unstructured":"Ho, A. S. et al. Genetic hallmarks of recurrent\/metastatic adenoid cystic carcinoma. J. Clin. Invest. 129, 4276\u20134289 (2019).","journal-title":"J. Clin. Invest."},{"key":"2518_CR20","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1158\/1078-0432.CCR-19-3758","volume":"26","author":"M Linxweiler","year":"2020","unstructured":"Linxweiler, M. et al. The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype. Clin. Cancer Res. 26, 2859\u20132870 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2518_CR21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"2518_CR22","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 (2010)."},{"key":"2518_CR23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703\u2013713 (2017).","journal-title":"Nat. Med."},{"key":"2518_CR24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"AP Weng","year":"2004","unstructured":"Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269\u2013271 (2004).","journal-title":"Science"},{"key":"2518_CR25","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood-2005-12-4956","volume":"108","author":"S Breit","year":"2006","unstructured":"Breit, S. et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 108, 1151\u20131157 (2006).","journal-title":"Blood"},{"key":"2518_CR26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JCO.2016.67.5264","volume":"35","author":"R Ferrarotto","year":"2017","unstructured":"Ferrarotto, R. et al. Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. J. Clin. Oncol. 35, 352\u2013360 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2518_CR27","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ng.2643","volume":"45","author":"AS Ho","year":"2013","unstructured":"Ho, A. S. et al. The mutational landscape of adenoid cystic carcinoma. Nat. Genet. 45, 791\u2013798 (2013).","journal-title":"Nat. Genet."},{"key":"2518_CR28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cels.2021.10.001","volume":"13","author":"Y Ciani","year":"2022","unstructured":"Ciani, Y. et al. Allele-specific genomic data elucidate the role of somatic gain and copy-number neutral loss of heterozygosity in cancer. Cell Syst. 13, 183\u2013193 (2022).","journal-title":"Cell Syst."},{"key":"2518_CR29","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."},{"key":"2518_CR30","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-016-1092-z","volume":"17","author":"Y \u015eenbabao\u011flu","year":"2016","unstructured":"\u015eenbabao\u011flu, Y. et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 17, 231 (2016).","journal-title":"Genome Biol."},{"key":"2518_CR31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48\u201361 (2015).","journal-title":"Cell"},{"key":"2518_CR32","first-page":"D498","volume":"48","author":"B Jassal","year":"2019","unstructured":"Jassal, B. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 48, D498\u2013D503 (2019).","journal-title":"Nucleic Acids Res."},{"key":"2518_CR33","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782\u2013795 (2013).","journal-title":"Immunity"},{"key":"2518_CR34","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550\u20131558 (2018).","journal-title":"Nat. Med."},{"key":"2518_CR35","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41591-019-0639-4","volume":"25","author":"D Chowell","year":"2019","unstructured":"Chowell, D. et al. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat. Med. 25, 1715\u20131720 (2019).","journal-title":"Nat. Med."},{"key":"2518_CR36","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy. Science 362, eaar3593 (2018).","journal-title":"Science"},{"key":"2518_CR37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41586-022-04895-8","volume":"607","author":"S Ghosh","year":"2022","unstructured":"Ghosh, S. et al. Enteric viruses replicate in salivary glands and infect through saliva. Nature 607, 345\u2013350 (2022).","journal-title":"Nature"},{"key":"2518_CR38","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934\u2013949 (2017).","journal-title":"Cell"},{"key":"2518_CR39","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251\u20131259 (2019).","journal-title":"Nat. Med."},{"key":"2518_CR40","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz, V. et al. NetMHCpan-4.0: improved peptide\u2013MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199, 3360\u20133368 (2017).","journal-title":"J. Immunol."},{"key":"2518_CR41","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.cell.2017.09.050","volume":"171","author":"R Marty","year":"2017","unstructured":"Marty, R. et al. MHC-I genotype restricts the oncogenic mutational landscape. Cell 171, 1272\u20131283 (2017).","journal-title":"Cell"},{"key":"2518_CR42","volume":"8","author":"HT Shin","year":"2017","unstructured":"Shin, H. T. et al. Prevalence and detection of low-allele-fraction variants in clinical cancer samples. Nat. Commun. 8, 1377 (2017).","journal-title":"Nat. Commun."},{"key":"2518_CR43","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413\u2013421 (2012).","journal-title":"Nat. Biotechnol."},{"key":"2518_CR44","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"2518_CR45","volume":"12","author":"S Valpione","year":"2021","unstructured":"Valpione, S. et al. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. Nat. Commun. 12, 4098 (2021).","journal-title":"Nat. Commun."},{"key":"2518_CR46","doi-asserted-by":"crossref","first-page":"eaah3560","DOI":"10.1126\/scitranslmed.aah3560","volume":"9","author":"W Roh","year":"2017","unstructured":"Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, eaah3560 (2017).","journal-title":"Sci. Transl. Med."},{"key":"2518_CR47","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/path.4260","volume":"231","author":"RO Emerson","year":"2013","unstructured":"Emerson, R. O. et al. High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer. J. Pathol. 231, 433\u2013440 (2013).","journal-title":"J. Pathol."},{"key":"2518_CR48","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1086\/282436","volume":"100","author":"HS Horn","year":"1966","unstructured":"Horn, H. S. Measurement of \u2018overlap\u2019 in comparative ecological studies. Am. Nat. 100, 419\u2013424 (1966).","journal-title":"Am. Nat."},{"key":"2518_CR49","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ccell.2021.10.001","volume":"39","author":"L Au","year":"2021","unstructured":"Au, L. et al. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell 39, 1497\u20131518 (2021).","journal-title":"Cancer Cell"},{"key":"2518_CR50","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41587-020-0656-3","volume":"39","author":"P Barennes","year":"2021","unstructured":"Barennes, P. et al. Benchmarking of T cell receptor repertoire profiling methods reveals large systematic biases. Nat. Biotechnol. 39, 236\u2013245 (2021).","journal-title":"Nat. Biotechnol."},{"key":"2518_CR51","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60\u201365 (2017).","journal-title":"Nature"},{"key":"2518_CR52","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1073\/pnas.1705327114","volume":"114","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst, A. O. et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1\u2013targeted therapy in lung cancer patients. Proc. Natl Acad. Sci. USA 114, 4993\u20134998 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2518_CR53","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641\u2013645 (2014).","journal-title":"Science"},{"key":"2518_CR54","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41591-022-01786-3","volume":"28","author":"SS Chandran","year":"2022","unstructured":"Chandran, S. S. et al. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat. Med. 28, 946\u2013957 (2022).","journal-title":"Nat. Med."},{"key":"2518_CR55","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","volume":"352","author":"CU Blank","year":"2016","unstructured":"Blank, C. U., Haanen, J. B., Ribas, A. & Schumacher, T. N. The \u2018cancer immunogram\u2019. Science 352, 658\u2013660 (2016).","journal-title":"Science"},{"key":"2518_CR56","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"2518_CR57","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41592-021-01142-2","volume":"18","author":"L Song","year":"2021","unstructured":"Song, L. et al. TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data. Nat. Methods 18, 627\u2013630 (2021).","journal-title":"Nat. Methods"},{"key":"2518_CR58","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nbt.3979","volume":"35","author":"DA Bolotin","year":"2017","unstructured":"Bolotin, D. A. et al. Antigen receptor repertoire profiling from RNA-seq data. Nat. Biotechnol. 35, 908\u2013911 (2017).","journal-title":"Nat. Biotechnol."},{"key":"2518_CR59","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B. et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat. Cancer 3, 108\u2013121 (2022).","journal-title":"Nat. Cancer"},{"key":"2518_CR60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature18945","volume":"536","author":"EME Verdegaal","year":"2016","unstructured":"Verdegaal, E. M. E. et al. Neoantigen landscape dynamics during human melanoma\u2013T cell interactions. Nature 536, 91\u201395 (2016).","journal-title":"Nature"},{"key":"2518_CR61","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li, K. et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct. Target. Ther. 6, 362 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2518_CR62","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1200\/JCO.22.02221","volume":"41","author":"R Ferrarotto","year":"2023","unstructured":"Ferrarotto, R. et al. Phase II clinical trial of axitinib and avelumab in patients with recurrent\/metastatic adenoid cystic carcinoma. J. Clin. Oncol. 41, 2843\u20132851 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2518_CR63","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2011-12-1-r1","volume":"12","author":"S Fisher","year":"2011","unstructured":"Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. 12, R1 (2011).","journal-title":"Genome Biol."},{"key":"2518_CR64","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"2518_CR65","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"2518_CR66","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491\u2013498 (2011).","journal-title":"Nat. Genet."},{"key":"2518_CR67","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"2518_CR68","doi-asserted-by":"publisher","unstructured":"Benjamin, D. et al. Calling somatic SNVs and indels with Mutect2. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/861054 (2019).","DOI":"10.1101\/861054"},{"key":"2518_CR69","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/bioinformatics\/btr665","volume":"28","author":"DE Larson","year":"2012","unstructured":"Larson, D. E. et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 28, 311\u2013317 (2012).","journal-title":"Bioinformatics"},{"key":"2518_CR70","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"2518_CR71","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568\u2013576 (2012).","journal-title":"Genome Res."},{"key":"2518_CR72","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/ng.3036","volume":"46","author":"A Rimmer","year":"2014","unstructured":"Rimmer, A. et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat. Genet. 46, 912\u2013918 (2014).","journal-title":"Nat. Genet."},{"key":"2518_CR73","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80\u201392 (2012).","journal-title":"Fly (Austin)"},{"key":"2518_CR74","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326 (2011).","journal-title":"Nat. Biotechnol."},{"key":"2518_CR75","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2018","unstructured":"Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941\u2013D947 (2018).","journal-title":"Nucleic Acids Res."},{"key":"2518_CR76","unstructured":"Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 2017, PO.17.00011 (2017)."},{"key":"2518_CR77","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).","journal-title":"Nucleic Acids Res."},{"key":"2518_CR78","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/nbt.3344","volume":"33","author":"SA Shukla","year":"2015","unstructured":"Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33, 1152\u20131158 (2015).","journal-title":"Nat. Biotechnol."},{"key":"2518_CR79","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/molbev\/msy116","volume":"35","author":"F Pierini","year":"2018","unstructured":"Pierini, F. & Lenz, T. L. Divergent allele advantage at human MHC genes: signatures of past and ongoing selection. Mol. Biol. Evol. 35, 2145\u20132158 (2018).","journal-title":"Mol. Biol. Evol."},{"key":"2518_CR80","doi-asserted-by":"crossref","first-page":"D423","DOI":"10.1093\/nar\/gku1161","volume":"43","author":"J Robinson","year":"2014","unstructured":"Robinson, J. et al. The IPD and IMGT\/HLA database: allele variant databases. Nucleic Acids Res. 43, D423\u2013D431 (2014).","journal-title":"Nucleic Acids Res."},{"key":"2518_CR81","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1126\/science.185.4154.862","volume":"185","author":"R Grantham","year":"1974","unstructured":"Grantham, R. Amino acid difference formula to help explain protein evolution. Science 185, 862\u2013864 (1974).","journal-title":"Science"},{"key":"2518_CR82","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng, D. T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251\u2013264 (2015).","journal-title":"J. Mol. Diagn."},{"key":"2518_CR83","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"2518_CR84","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/bioinformatics\/bts356","volume":"28","author":"L Wang","year":"2012","unstructured":"Wang, L., Wang, S. & Li, W. RSeQC: quality control of RNA-seq experiments. Bioinformatics 28, 2184\u20132185 (2012).","journal-title":"Bioinformatics"},{"key":"2518_CR85","doi-asserted-by":"crossref","first-page":"e1003118","DOI":"10.1371\/journal.pcbi.1003118","volume":"9","author":"M Lawrence","year":"2013","unstructured":"Lawrence, M. et al. Software for computing and annotating genomic ranges. PLoS Comput. Biol. 9, e1003118 (2013).","journal-title":"PLoS Comput. Biol."},{"key":"2518_CR86","doi-asserted-by":"crossref","first-page":"D670","DOI":"10.1093\/nar\/gku1177","volume":"43","author":"KR Rosenbloom","year":"2015","unstructured":"Rosenbloom, K. R. et al. The UCSC Genome Browser database: 2015 update. Nucleic Acids Res. 43, D670\u2013D681 (2015).","journal-title":"Nucleic Acids Res."},{"key":"2518_CR87","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"2518_CR88","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108\u2013112 (2009).","journal-title":"Nature"},{"key":"2518_CR89","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"2518_CR90","doi-asserted-by":"crossref","DOI":"10.1186\/s12864-020-6483-6","volume":"21","author":"SR Selitsky","year":"2020","unstructured":"Selitsky, S. R. et al. Virus expression detection reveals RNA-sequencing contamination in TCGA. BMC Genomics 21, 79 (2020).","journal-title":"BMC Genomics"},{"key":"2518_CR91","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","volume":"25","author":"R Benayed","year":"2019","unstructured":"Benayed, R. et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. Clin. Cancer Res. 25, 4712\u20134722 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2518_CR92","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","volume":"20","author":"Z Zheng","year":"2014","unstructured":"Zheng, Z. et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat. Med. 20, 1479\u20131484 (2014).","journal-title":"Nat. Med."},{"key":"2518_CR93","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1093\/bioinformatics\/btz879","volume":"36","author":"G Fotakis","year":"2019","unstructured":"Fotakis, G., Rieder, D., Haider, M., Trajanoski, Z. & Finotello, F. NeoFuse: predicting fusion neoantigens from RNA sequencing data. Bioinformatics 36, 2260\u20132261 (2019).","journal-title":"Bioinformatics"},{"key":"2518_CR94","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3680","volume":"4","author":"CS Carlson","year":"2013","unstructured":"Carlson, C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat. Commun. 4, 2680 (2013).","journal-title":"Nat. Commun."},{"key":"2518_CR95","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/j.1538-7305.1948.tb01338.x","volume":"27","author":"CE Shannon","year":"1948","unstructured":"Shannon, C. E. A mathematical theory of communication. Bell Syst. Tech. J. 27, 379\u2013423 (1948).","journal-title":"Bell Syst. Tech. J."},{"key":"2518_CR96","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/163688a0","volume":"163","author":"EH Simpson","year":"1949","unstructured":"Simpson, E. H. Measurement of diversity. Nature 163, 688\u2013688 (1949).","journal-title":"Nature"},{"key":"2518_CR97","first-page":"215","volume":"2","author":"M Morisita","year":"1959","unstructured":"Morisita, M. Measuring of the dispersion of individuals and analysis of the distributional patterns. Mem. Fac. Sci. Kyushu Univ. Ser. E Biol. 2, 215\u2013235 (1959).","journal-title":"Mem. Fac. Sci. Kyushu Univ. Ser. E Biol."},{"key":"2518_CR98","unstructured":"Nazarov, V. et al. Immunarch: bioinformatics analysis of T-cell and B-cell immune repertoires. GitHub https:\/\/immunarch.com\/, https:\/\/github.com\/immunomind\/immunarch (2023)."},{"key":"2518_CR99","doi-asserted-by":"crossref","first-page":"100758","DOI":"10.1016\/j.xpro.2021.100758","volume":"2","author":"C Cimen Bozkus","year":"2021","unstructured":"Cimen Bozkus, C., Blazquez, A. B., Enokida, T. & Bhardwaj, N. A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses. STAR Protoc. 2, 100758 (2021).","journal-title":"STAR Protoc."},{"key":"2518_CR100","doi-asserted-by":"crossref","unstructured":"Valero, C. et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat. Commun. 12, 729 (2021).","DOI":"10.1038\/s41467-021-20935-9"},{"key":"2518_CR101","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756 (2018).","journal-title":"Genome Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02518-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02518-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02518-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T16:07:09Z","timestamp":1702483629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02518-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":101,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2518"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02518-x","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]},"assertion":[{"value":"2 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.L.H. reports research funding for clinical trials from Allos Therapeutics, Astellas Pharma, AstraZeneca, Bayer, Ayala Pharmaceuticals, Bristol Myers Squibb, Genentech, Celldex Therapeutics, Daiichi Sankyo, Eisai., Elevar Therapeutics, Eli Lilly & Company, Genentech\/Roche, Hoikpia, Kolltan Pharmaceuticals, Kura Oncology, Merck, Novartis, Pfizer, Poseida and Verastem; service in consulting\/advisory roles for AffyImmune Therapeutics, AstraZeneca, Ayala Pharmaceuticals, Bristol Myers Squibb, Cellestia Biotech, Coherus, CureVac, Eisai, Elevar Therapeutics, Exelixis, Expert Conncet, Genzyme, InxMed, Kura Oncology, McGivney Global Advisors, Merck, Novartis, CureVac, Prelude Therapeutics, Regeneron, Rgenta, Remix Therapeutics, Sanofi, Sun Pharma, the Chemotherapy Foundation and TRM Oncology; service on speakers\u2019 bureaus for Medscape, Omniprex America, Novartis and Physician Education Resource; and receipt of travel\/accommodations expenses from Janssen Oncology, Merck, Kura Oncology, Ignyta, Ayala Pharmaceuticals and KLUS Pharma, outside the submitted work. A.L.H. is also inventor on a patent for the use of lesional dosimetry methods for tailoring targeted radiotherapy in cancer. L.G.T.M. is listed as an inventor on intellectual property held by MSK on using tumor mutation burden to predict immunotherapy response, with pending patent, which has been licensed to Personal Genome Diagnostics. T.A.C. reports, all outside the submitted work, being a co-founder of Gritstone Oncology and holding equity; holding equity in An2H and acknowledging grant funding from Bristol Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H and Eisai; having served as an advisor for Bristol Myers, MedImmune, Squibb, Illumina, Eisai, AstraZeneca and An2H; andd being an inventor on intellectual property held by MSK on using tumor mutation burden to predict immunotherapy response, with pending patent, which has been licensed to Personal Genome Diagnostics. C.A.K. is a scientific co-founder and equity holder of Affini-T Therapeutics; is a compensated member of the scientific and\/or clinical advisory boards for Achilles Therapeutics, Affini-T Therapeutics, Aleta BioTherapeutics, Bellicum Pharmaceuticals, Catamaran Bio, Obsidian Therapeutics and T-knife; has consulted for Bristol Myers Squibb, Decheng Capital, PACT Pharma and Roche\/Genentech; and has patents broadly related to cell and gene therapy outside the scope of this work. N.R. reports research funding from ArcherDx and Repare Therapeutics and personal fees from Illumina, PaigeAI and Pfizer Canada, outside the submitted work. E.J.S. reports institutional research funding from Merck, outside the submitted work, and personal fees from Eli Lilly & Company, Blueprint Medicines Corporation, Regeneron Pharmaceuticals, Loxo Oncology and Eisai, outside the submitted work. L.A.D. reports research funding and personal fees from CUE-101, Eisai, CUE-101, Replimune Group and Regeneron Pharmaceuticals and service on an advisory board at Merck, outside the submitted work. V.T. reports holding stock in Infinity Pharmaceuticals, Bluebird Bio and Mersana Therapeutics. C.L.Z. is linked to investigator-initiated clinical trials in collaboration with Bristol Myers Squibb, outside the submitted work. D.G.P. reports grants from the National Institutes of Health (NIH) and the Philanthropy\u2013Serra Fund; research support from Hookipa Pharma; and personal fees from Nykode and Hookipa Pharma, outside the submitted work. B.B. is an employee of AstraZeneca. Z.N. is an employee of PPD, part of Thermo Fisher Scientific. W.Y. is an employee of Eli Lilly & Company. V.M. is listed as an inventor on a patent assigned to MSK broadly related to determinants of cancer response to immunotherapy. J.L.V., S.J., C.W.R.F., F.K., C.Y.H., M.P., N.K., R.M.S., I.O., A.K., L.S.M., J.V.F., K.K.N., J.E. and S.H. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}